JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
James A. Caccitolo
Thomas A. Orszulak
Hartzell V. Schaff
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caccitolo, J. A.
Right arrow Articles by Schaff, H. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caccitolo, J. A.
Right arrow Articles by Schaff, H. V.
Related Collections
Right arrow Valve disease

J Thorac Cardiovasc Surg 2001;122:656-664
© 2001 The American Association for Thoracic Surgery

Surgery for Aquired Cardiovascular Disease (ACD)

Operation for anorexigen-associated valvular heart disease

James A. Caccitolo, MD, Heidi M. Connolly, MD, David S. Rubenson, MD, Thomas A. Orszulak, MD, Hartzell V. Schaff, MD

From the Divisions of Cardiovascular Surgery and Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn, and the Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, Calif.

Received for publication Oct 6, 2000. Revisions requested Jan 17, 2001; revisions received April 2, 2001. Accepted for publication April 5, 2001. Address for reprints: Hartzell V. Schaff, MD, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Abstract

Objectives: Recently, valvular regurgitation has been observed in patients who have taken fenfluramine or dexfenfluramine with or without phentermine. This study describes the clinical, echocardiographic, and pathologic findings of anorexigen-associated valvular heart disease and the surgical interventions required to treat it.
Methods: We reviewed clinical information on 14 patients with severe anorexigen-associated valvular disease who underwent cardiac operations.
Results: Thirteen women (mean age 44.2 ± 5.3 years) received fenfluramine, 58.5 ± 22.3 mg/day, and phentermine, 32.1 ± 11.4 mg/day, for an average of 12.1 ± 7.3 months before presentation. One woman received dexfenfluramine, 30 mg/day for 13 months, and phentermine, 60 mg/day, concomitantly for 6 months. Presenting symptoms included dyspnea (12 cases), palpitations (3), and atypical chest pain (3). Six patients had heart failure, and 4 had a new murmur. Echocardiography demonstrated severe mitral valve regurgitation in all patients. Seven also had aortic regurgitation, and 4 had significant tricuspid regurgitation. Four patients had successful mitral valve repair, 1 with concomitant aortic valve repair. Ten additional patients eventually required mitral valve replacement, 5 with concomitant aortic valve replacement. Excised valves demonstrated a glistening white appearance with plaque-like encasement of leaflets and chordae. Focal surface proliferation and fibrosis with a "stuck-on" appearance was consistently found.
Conclusions: Anorexigen use may lead to severe multivalvular regurgitation with characteristic echocardiographic and pathologic findings. Recognition of drug-induced valvulopathy is important because of widespread use of these medications and the uncertain natural history of the disease. Early surgical experience suggests that valve repair is possible in these young patients.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 by The American Association for Thoracic Surgery.